Nanexa strengthens the organization

News

 

Uppsala 29th August 2019

 

Nanexa strengthens the organization

Nanexa expands the workforce by two people in operational positions. Wictor Dahlström, MSc, who has many years of experience in quality systems in the pharmaceutical industry, including from AstraZeneca, is hired as “Quality Assurance Officer”. Matias Tasel, BSc, strengthens the team in the production of materials for our own project and for our collaborative partners. Both start at Nanexa on September 2.

 

CEO David Westberg comments:

Our partnerships are increasing in number and intensity, and as Nanexa matures as a company. A natural consequence of this is that we increase our capacity to produce samples for our partners, while continuing to focus on further development of our own NEX-18 project, technology development and patents. Matias will strengthen that capacity, which is something I see as very positive.

We are also entering a phase where we will produce materials for clinical studies in the NEX-18 project. To ensure that we meet the regulatory requirements associated with such manufacturing, we are now introducing a so-called GMP (Good Manufacturing Practice) quality system in the company. For the implementation of this and for ongoing quality issues, Wiktor comes in as an important reinforcement.

It can also be mentioned that the introduction of a GMP quality system will strengthen our position vis-à-vis potential partners as it enables the production of clinical trial material even in partner-driven projects.

 

For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail: david.westberg@nanexa.se

www.nanexa.com

 

About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.